MedTrace Logo

A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma

NCT03332017 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 217

Last updated 2026-02-18

Study results available
· View outcomes & findings →

Summary

This clinical study examined the safety and efficacy of the combination of zanubrutinib and obinutuzumab versus obinutuzumab alone in adults with follicular lymphoma whose disease returned after or did not respond to prior therapy.

Conditions

  • Relapsed/Refractory Follicular Non-Hodgkin Lymphoma

Interventions

DRUG

Zanubrutinib

Oral administration as a capsule

DRUG

Obinutuzumab

Intravenous administration

Sponsors & Collaborators

  • BeiGene

    lead INDUSTRY

Principal Investigators

  • Study Director · BeiGene

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-14
Primary Completion
2021-10-08
Completion
2024-12-27
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belarus
  • Bulgaria
  • Canada
  • China
  • Czechia
  • France
  • Germany
  • Italy
  • New Zealand
  • Poland
  • Russia
  • South Korea
  • Spain
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03332017 on ClinicalTrials.gov